Shanghai Hengrui Pharmaceutical Co., Ltd.

This study tests a new drug called SHR6508 in 303 adults on hemodialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels get too high. The drug is given as an injection to help control these hormone levels and related minerals like calcium and…

This early-stage trial tested an experimental drug called SHR-1707 in 33 people with mild memory problems or mild Alzheimer's disease. The drug is an antibody given through a vein, designed to target and clear amyloid plaques in the brain. The main goal was to check safety and si…

This study tested a new drug called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (a type of eczema). Participants received one of three doses of the drug or a placebo. The main goal was to see if the drug could reduce eczema severity by at least 75% after 16 w…

This study looked at the long-term safety of the drug SHR-1819 in 79 adults with moderate to severe eczema who had already taken part in earlier studies of the same drug. Researchers tracked side effects and how well the drug controlled the disease over time. The goal was to see …

This study tested a new drug called SHR6508 in 498 adults on hemodialysis who have secondary hyperparathyroidism, a condition where the parathyroid glands make too much hormone. The drug is given during dialysis and was compared to an existing oral medication, cinacalcet. The goa…

This completed Phase 1 study looked at how a radioactive form of the drug SHR6508 is processed and eliminated in 5 Chinese adults on hemodialysis who have secondary hyperparathyroidism. The main goal was to measure how much radioactivity ends up in urine and stool, and to identif…